American Heart Association thinks pharmacists can play a bigger role in AFib care

Atrial fibrillation (AFib) is one of the most common heart complications in the United States, but many AFib patients fail to take the medications prescribed by their cardiologists. The American Heart Association (AHA) thinks pharmacists could help reverse that trend by participating more in patient care by providing helpful communication at the pharmacy, or even playing a more involved role in patient management.

The AHA has announced that engaging with U.S. pharmacists represents the next phase of its ongoing Four F’s of Atrial Fibrillation initiative, which is focused on addressing barriers to care for undertreated AFib patients through series of roundtable discussions, webinars and podcast episodes. The project sponsored by the Bristol Myers Squibb and Pfizer Alliance.

“Pharmacists are an integral part of the multidisciplinary team to optimize care for individuals with atrial fibrillation,” Cody Parsons, APh, PharmD, BCCCP, manager of clinical operations for Stanford Health Care's cardiovascular health service line, said in an AHA statement. “The insight of pharmacists in evaluating the medical complexity and use of multiple medications is essential in facilitating safe and effective anticoagulation and ultimately preventing life-altering medical consequences of AFib.”